UBS Group’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

UBS Group’s Portfolio NVET Stock Details NVET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-2,445	Closed	-$16K	–	8340
2017 Q2	$16K	Buy	+2,445	New	+$15.4K	﹤0.01%	6481
2017 Q1	–	Sell	-2,750	Closed	-$10K	–	8319
2016 Q4	$10K	Sell	2,750 -346	-11%	-$1.43K	﹤0.01%	6954
2016 Q3	$13K	Buy	+3,096	New	+$14.7K	﹤0.01%	6636
2016 Q2	–	Sell	-1,354	Closed	-$4K	–	8207
2016 Q1	$4K	Buy	+1,354	New	+$4.42K	﹤0.01%	7139
2015 Q4	–	Sell	-2,007	Closed	-$7K	–	8765
2015 Q3	$7K	Buy	2,007 +578	+40%	+$2.63K	﹤0.01%	7545
2015 Q2	$7K	Buy	1,429 +762	+114%	+$5.28K	﹤0.01%	7739
2015 Q1	$5K	Buy	+667	New	+$6.31K	﹤0.01%	8152

UBS Group's NVET Position: Q3 2017 in Review

UBS Group sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q3 2017, closing a stake of 2,445 shares — an estimated $16K sold.

UBS Group first reported a position in NVET in Q1 2015 and held it in 7 quarters. The position peaked at $16K in Q2 2017. 0 funds tracked by Wall St. Rank hold NVET as of Q3 2017.

UBS Group reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q3 2017 after selling out during the quarter.
UBS Group sold 2,445 Nexvet Biopharma plc Ordinary Shares shares in Q3 2017, an estimated $16K.
UBS Group first reported a position in Nexvet Biopharma plc Ordinary Shares in Q1 2015 and held it in 7 quarters.
UBS Group's Nexvet Biopharma plc Ordinary Shares position peaked at $16K in Q2 2017.
0 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q3 2017.

Based on UBS Group's 13F filing for Q3 2017, filed 14 Nov 2017.